$JNJ

Broadhurst Vanessa sold $5.8M of JNJ

Broadhurst Vanessa (EVP, Global Corp Affairs) sold 23,054 shares of JOHNSON & JOHNSON (JNJ) at $251.27 ($5.79M total) on 2026-07-20.

Original reporting
SEC EDGAR · Broadhurst Vanessa
Published Jul 21, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 21, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$JNJ
Neutral
high confidence
Mentioned
$JNJ
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new company-specific fundamentals or forward-looking guidance.

02

Market read

Traders may monitor for patterns in insider activity, but this single sale is unlikely to drive a material repricing without additional catalysts.

03

What to watch

The text notes no 10b5-1 plan and shows post-transaction holdings, but it still lacks context on compensation, tax needs, or whether sales were part of a broader pattern.

Relevance 6/10Novelty 2/10Timing: Filed 2026-07-21, covering a sale executed 2026-07-20.

Background

The article is an SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Johnson & Johnson disclosed an EVP global corporate affairs open-market sale of 23,054 shares at $251.2660 on 2026-07-20 via Form 4.

Expected impact

Likely minimal price impact; any effect is short-lived unless accompanied by other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) with no guidance, earnings, legal, or operational catalyst included in the text.

Market effects

No sector read-through; this is company-specific insider trading without new regulatory, product, or litigation facts.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for diversification or liquidity, so the signal may be noise rather than bearish information.

Key entities

  • Johnson & Johnson

    Subject of the Form 4 insider transaction disclosure.

  • Broadhurst Vanessa

    EVP, Global Corp Affairs who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Johnson & Johnson outlook: bull and bear cases after Q3 earnings

Johnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.

$JNJMedAI 8/10

Johnson & Johnson CFO taps internal investment for medtech growth

Johnson & Johnson CFO Joseph Wolk stated the company will use internal investments to drive medtech growth, aiming for double-digit growth by 2030. Q3 medtech sales rose 2.5%, below expectations, but innovative medicine sales offset this. J&J reported $25B in net sales, up 6%, but net earnings dropped 96% YoY due to M&A and litigation costs. The company expects $101B-$101.4B in 2026 sales.

$JNJHigh

Johnson & Johnson PR: Tylenol Recall to Talc Settlement

Johnson & Johnson (J&J) announced a $5.5B talc settlement on July 27, 2026, covering 76,000 ovarian cancer claims. The company expects to pay $3B in 2027, with the total potentially reaching $7B. J&J is also separating its orthopaedics business, DePuy Synthes, with a 2025 sales of $9.3B. Additionally, Kenvue, J&J's consumer health spinoff, was acquired by Kimberly-Clark for $48.7B in 2025. J&J's 2025 sales outlook was $93.5B to $93.9B.

$JNJHighAI 8/10

J&J posts weak medical device sales, shares fall

Johnson & Johnson reported medical device sales of $8.6B, missing estimates of $8.71B, citing geopolitical issues. Shares fell 6%. CFO Joe Wolk attributed weakness to Middle East conflict, European austerity, and China pricing. The company raised its full-year sales forecast to $101.2B and adjusted earnings to $11.10 per share. Pharmaceutical sales rose 7.7% to $16.76B, with Tremfya sales up 68% to $2.4B.